

Lyon Hepatology Institute - IHU EVEREST

intEgratiVE RESeArch in hepaTology




Scientific Director: Fabien Zoulim
Deputy Director: Massimo Levrero
Executive Director: Catherine Oudin





Why a Research Institute (IHU) for Liver Diseases?

Healthy Cirrhosis Cancer



- Global prevalence: 1,5 billion
- > 2 million deaths/year (cirrhosis & liver cancer)
- Alcohol and Metabolic (NAFLD) *epidemics*
- Overall health costs x4



Chronic Liver Diseases (CLDs) Challenges

- Disease and patient heterogeneity
 - Few curative treatments
- New biomarkers for prognosis & stratification
 - New targets for curative treatments
 - New technologies for organ preservation

EVEREST - New Frontiers and Ambition

Integrate → *Basic & clinical research with social sciences and public health*
→ *All liver diseases across etiologies and stages*

New paradigms for CLD management

- ✓ Early diagnosis and interventions
- ✓ New disease classifiers for treatment personalization
- ✓ Discovery of new curative treatments




Reduce the impact of CLDs

- ✓ Reduce premature morbidity and mortality
- ✓ Decrease the impact on working life lost
- ✓ Decrease public health and social costs

EVEREST: The French Comprehensive Liver Center
A unique model of liver institute

Why in Lyon?



Exciting Multidisciplinary research

18 Research teams
114 Tenured scientists



Excellence in clinical management & research

13 Clinical units
99 Clinicians (H/HU)



162 Clinical studies (2017-2021)
Clinical trials: **1335** patients
Cohorts: **4590** patients

International recognition Collaborations and networks



21 Countries: academic collaborations
10 Countries: industrial network

A dynamic environment



A strong institutional commitment



An IHU to leverage and shape
unique synergies around liver diseases

EVEREST - Research Teams



CRCL U1052
Centre de Recherche en
Cancérologie de Lyon



3dFab
Institut de Chimie et
Biochimie Moléculaires et
Supramoléculaires

u1213nutrition

ISA
Institut des Sciences
Analytiques



PaThLiv Unit
Pathobiology and Therapy
of Liver diseases

NUDICE U1213
Nutrition, Diabète et
Cerveau

Medical Imaging
Hepato-biliary
pathologies, liver
transplantation



CarMeN U1060
Cardiovasculaire,
Métabolisme,
Diabétologie, Nutrition



LBBE
Laboratoire de Biométrie
et Biologie Evolutive



CIRI U1111
Centre International de
Recherche en Infectiologie

U1296
Défense, Santé,
Environnement

PSP
Pôle de Santé Publique




UNIVERSITÉ LUMIÈRE LYON 2
UNIVERSITÉ DE LYON




RESHAPE
Research on Healthcare Performance

RESHAPE – U1290
Research on Healthcare
Performance

EVEREST - Models, Technologies and Platforms



EVEREST - Scientific Strategy



EVEREST workpackages

Basic and translational science

WP1 Curing HBV and HDV:
*from virus persistence to
innovative targets*

WP2 Liver integrative biology:
*interplay between
energetic metabolism,
inflammation and epigenetics*

WP3 Hepatic critical care:
*targeting perioperative
liver injury*

Translational science for clinical research

WP4 Multiomics profiling:
*towards an actionable
blueprint of liver diseases*

**WP5 Clinical cohorts
and trials**

WP6 Improving care:
*impact of innovation on clinical
care pathways and health system*

WP7 Data Science, data integration and modelling
Precision medicine, public health & economic assessment

WP8 Innovative Training and Education Programs

WP9 Exploitation and industrial transfer

EVEREST – Strong and Durable Support from Founders

HCL
HOSPICES CIVILS
DE LYON

Hospices Civils de Lyon - North Hospital



EVEREST Building - 4500 m²

Research labs
Translational platforms
Flex lab / start-ups
Liver patient home
Dedicated Clinical Trial Unit

- ✓ **Dedicated EVEREST positions**
- ✓ **Dedicated staff** for fast track support of clinical investigations and grant applications
- ✓ **Core grant for the new liver research unit PaThLiv**

EVEREST - Transforming Effect in Time and Space

Unite scientists, health professionals & patients
Innovation for cure of liver diseases

Innovation, Discovery and Transfer

Excellence and Attractiveness



Promote healthy liver

Train the *new leaders* in liver sciences

Transform knowledge and healthcare in liver diseases



"This venture could serve as a model for future similar comprehensive [hepatology] centres of excellence in other European countries."

EASL letter of support
– 14 October 2022

International influence & leadership